Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Boucher

Showing results (101-110 of 109) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 109 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal AdenocarcinomaHao Liu, Kamila Naxerova, Matthias Pinter, et al.
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Cancer Discovery|June 2, 2016
Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to ChemotherapyJoao Incio, Hao Liu, Priya Suboj, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaTheodore S Hong, David P Ryan, Darrell R Borger, et al.
JAMA Oncology|May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Pageof 11

Showing results (101-110 of 109) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2017
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal AdenocarcinomaHao Liu, Kamila Naxerova, Matthias Pinter, et al.
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Cancer Discovery|June 2, 2016
Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to ChemotherapyJoao Incio, Hao Liu, Priya Suboj, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics|May 29, 2014
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaTheodore S Hong, David P Ryan, Darrell R Borger, et al.
JAMA Oncology|May 31, 2019
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical TrialJanet E Murphy, Jennifer Y Wo, David P Ryan, et al.
Pageof 11